Management of Atrial Fibrillation in Patients with Myocardial Infarction

Introduction to Anticoagulation Therapy

The American College of Cardiology recommends continuing P2Y12 inhibitor (preferably clopidogrel) plus Direct Oral Anticoagulant (DOAC), and discontinuing aspirin, with triple therapy considered for the first month post-MI if ischemic risk outweighs bleeding risk 1
The American College of Cardiology prefers DOACs over vitamin K antagonists (warfarin) due to lower risk of major, fatal, and intracranial bleeding 1

Adding a proton pump inhibitor is recommended to reduce gastrointestinal bleeding risk when using anticoagulation, according to the American College of Cardiology 1
The international normalized ratio (INR) should be maintained between 2.0 and 3.0 if vitamin K antagonists are used 2

Combining aspirin with anticoagulation in patients with stable coronary disease does not reduce stroke or systemic embolism rates, but significantly increases major bleeding risk, with no additional benefit for myocardial infarction prevention, as recommended by the American College of Cardiology 1
Oral anticoagulation alone is recommended for patients with atrial fibrillation and stable coronary artery disease, according to the American College of Cardiology, European Society of Cardiology, and American College of Chest Physicians 2, 3, 4, 1
If more than 12 months have passed since an acute coronary syndrome, stent implantation, or coronary artery bypass grafting, oral anticoagulation alone is recommended 1
In patients with a CHA₂DS₂-VASc score of 2 or higher, oral anticoagulation is sufficient for the prevention of ischemic events 2, 3

Triple therapy (anticoagulant + dual antiaggregation) is recommended for 1-3 months in patients with a high risk of bleeding, followed by dual therapy (anticoagulant + clopidogrel) for up to 12 months 3, 1
After 12 months, oral anticoagulation alone is recommended 4, 1
Aspirin should be discontinued after 1-4 weeks of triple therapy and continue P2Y12 inhibitor (preferably clopidogrel) and oral anticoagulant, as recommended by the American Heart Association and American College of Cardiology 5, 6

High bleeding risk factors, such as previous intracranial hemorrhage, recent major bleeding, severe renal impairment, low body weight, age >75 years, or concomitant use of NSAIDs, should be carefully monitored when on dual therapy 7
Previous spontaneous intracranial hemorrhage is a major criterion for high bleeding risk, relevant to patients with brain masses, as identified by the Academic Research Consortium 5
Brain mass characteristics, such as highly vascular tumors, size, location, and malignancy potential, all factor into bleeding risk assessment, guiding the decision to discontinue aspirin 5
Using a proton pump inhibitor can reduce gastrointestinal bleeding risk when dual therapy is necessary 8, 7
Combining aspirin with Eliquis substantially increases bleeding risk, and the European Society of Cardiology guidelines recommend against it 7

Aspirin should ideally be discontinued 7-10 days before any planned neurosurgical intervention to allow for new platelet production, considering the patient's cardiovascular risk profile 9
Plan for resumption of aspirin or alternative antiplatelet agents 2-4 weeks post-procedure if hemostasis is adequate, considering the patient's cardiovascular risk profile and the presence of a brain mass 10
Abrupt discontinuation without consultation is not recommended, and always consult with a cardiologist before discontinuing antiplatelet therapy in patients with recent ACS or stent placement, as advised by the European Society of Gastrointestinal Endoscopy and American College of Cardiology 11, 9